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Summary We describe here a murine monoclonal antibody of the IgG2a isotype which was generated
against the SW2 human small cell carcinoma cell line. The antibody, SWA11, was shown to bind to a
partially defined antigen preferentially expressed on cell lines of small cell carcinoma origin. In vitro binding
studies revealed 6.1 x 105 antigenic sites on the SW2 cell line and the Ka to be 1.2 x 109 M-1. Following
injection into mice bearing 1-2cm3 SW2 xenografts, SWA11 showed strong selective accumulation in the
small cell heterotransplants with a tumour to blood ratio of 7.5:1 at day 4. Other tumour to organ ratios
were similarly high at 19:1, 22:1 and 12:1 for liver, kidney and spleen respectively. The absolute amount of
SWA 1I which localised was 10.5% of total injected material per gram tumour at day 2 and this level did not
markedly decrease by day 4. The high ability of SWAI1 to localise to SCC xenografts was confirmed by
external gamma scintigraphy. The potential application of SWA11 as a model system for in vivo
radioimmunotherapy is discussed.
Lung cancer is currently the most lethal of malignant
conditions in the Western world and is predicted to remain
so for the foreseeable future (De Leij et al., 1987). Of the
five major groups of lung cancer, only small cell cancer
(SCC) is observed to be highly chemo- and radiosensitive
and yet the prognosis for patients with SCC remains very
poor. Approximately 60% of SCC patients have metastases
at the time of first presentation, restricting the use of surgery
or radiotherapy and causing a strong reliance on the use of
chemotherapy. The poor prognosis for SCC relates not only
to its early and extensive metastasis but to its high rate of
growth and the post-treatment emergence of chemoresistance
(De Leij et al., 1987). This invasive nature indicates the need
to develop new agents with systemic efficacy against SCC.
The use of monoclonal antibodies (MAbs) for diagnosis
(Cuttitta et al., 1984), imaging (Mach et al., 1981; Smedley et
al., 1983) and now therapy (Lobuglio et al., 1986; Epenetos
et al., 1987) of malignant disease is an increasingly realistic
objective. MAbs generated against surface antigens of SCC
can be divided according to the nature and expression of
their target antigens into five main clusters, as defined at the
International Workshop on SCC, London 1987 (Souhami et
al., 1988). We have produced a panel of antibodies belonging
to clusters w4 and 5, some of which have been previously
described (Stahel et al., 1988; Waibel et al., 1987, 1988). This
paper describes the antibody SWAI1, which appears to
belong to cluster w4 and which has been selected for in vivo
evaluation because of its strong reactivity with both classic
and variant SCC lines in vitro. This antibody is characterised
by a very high capacity for in vivo localisation, relatively low
retention in non-target organs and persistence at the target
tumour. These characteristics suggest SWAl1 to be a suit-
able candidate for use in the establishment of an in vivo
model for the radioimmunotherapy of SCC tumours and in
the long-term for use in clinical studies on imaging and
therapy. The therapeutic application of such reagents as
vehicles for the selective delivery of cytotoxins, or isotopes
for imaging or therapy of SCC, is desirable in view of the
present poor prognosis for patients with this disease (De
Vita et al., 1985; Carney, 1987).
Materials and methods
Cell lines
The SCC cell line SW2 was established in the laboratory of
Dr S.D. Bernal, Dana Farber Institute. It was routinely
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grown in RPMI medium supplemented with 1 mM glutamine
and 10% fetal calf serum. Cell line CORL47 was obtained
from Dr P. Twentyman, MRC, Hills Road, Cambridge,
England. The other cell lines employed for screening of
antibody reactivity were generated in our own laboratory, or
obtained from ATCC or from sources that have already
been described (Stahel et al., 1986).
Monoclonal antibodies
Our procedure for antibody generation has been previously
described (Stahel et al., 1985b). Antibodies SWAI1, SWA20,
SWA21 and SWA22 were purified as follows. A 30-55%
ammonium sulphate fraction was taken from culture super-
natant and adsorbed onto a protein A column in PBS. The
adsorbed IgG was eluted with 100mm citrate buffer (pH 4.5)
and then dialysed against 10mm phosphate buffer (pH 6.8)
containing 0.01 mM CaCl2. The antibody was then applied to
a hydroxylapatite column (Bio-Gel HPHT, Bio-Rad, Rich-
mond, CA) and eluted with a linear gradient to 350mM
phosphate.
Reactivity with viable cells by immunofluorescence and
haemagglutination
The reactivity of SWAI1, SWA21 and SWA22 with a panel
of in vitro SCC lines, primary cultures of bronchial epi-
thelium and peripheral white blood cells was determined by
indirect immunofluorescence. Cells were washed three times
in PBS (1% BSA, 0.02% azide), dispensed at 105 cells per
tube and incubated for 30min at 37°C with 100 jIl culture
supernatant. After further washing the cells were incubated
with 50pl goat anti-mouse FITC conjugate (1/20 dilution)
for 30min at 37°C. Rim pattern fluorescence, indicative of
surface antigen, was viewed using a Zeiss epifluorescence
microscope. Reactivity with a panel of red blood cells
expressing defined blood group antigens was assessed by
direct haemagglutination assay within the Haematology
Department, Universitaetsspital, Zurich.
Competitive solid phase radioimmunoassay
Target cells were fixed to 96-well plates. The plates were
coated with poly-L-lysine and 5 x 104 cells fixed to each well
using glutaraldehyde. Plates were stored at 4°C in PBS
containing 1% BSA and 0.2% sodium azide. Prior to use the
plates were incubated with wash buffer for 30min to prevent
non-specific binding (Tris-buffered saline, 5% non-fat milk
and 1% gelatine). Unlabelled antibodies SWA21 and
SWA22, which show the same pattern of tissue reactivity as
SWAl1 and which were grouped as cluster w4 at the
International Workshop on SCC, London, 1987, were added
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at saturating concentration to the plate with SWAl1 acting
as positive control and SWA20 (Workshop cluster 5A) as
negative control. Incubation was performed for 1 h at 37°C
and then the plates were washed four times with PBS and
1% BSA. Radiolabelled SWAl 1 was then added (at a
concentration giving one-half maximal binding in the
absence of competition) and further incubation performed at
37°C for one hour. After final washing (x 4) individual
wells were cut out and counted in a gamma counter.
Antibody labelling techniques
lodogen 0.1mg (Pierce) was dissolved in 0.2ml chloroform
and added to a 1 ml vial. The solvent was evaporated with a
gentle stream of nitrogen and then 0.5mg of antibody in
0.25ml PBS was added. 1311 or 1251 (0.3mCi in 0.03ml)
was added and the reaction continued for 15 min at 10°C
with stirring. The reaction mixture was applied to a pre-
packed Sephadex G50 column which had been equilibrated
with PBS (0.05M phosphate buffer, 0.1M sodium chloride).
The solution was sterilised by passage through a 0.22,im
filter (Millex GV). Human serum albumin 0.04ml (25%) was
added as a protein carrier and then radiochemical purity was
assessed by thin layer chromatography using CEL300 poly-
gram (Marchery Nagel) and methanol (85%). Radiochemical
purity was generally in excess of 95%.
In vitro immunoreactivity
To determine the biological activity of radiolabelled SWAl1,
SW2 cells were washed three times in PBS (with 5% non-fat
milk, 0.05% azide) and varying cell numbers were then
incubated for 2 h at 4°C with a fixed amount of radio-
labelled antibody (690,000c.p.m.), After washing the activity
in the cell pellet was counted. The number of counts
remaining unbound was plotted against the reciprocal of the
cell number so that the intercept on the y-axis indicates the
theoretical unreactive fraction. The difference between the
input and the estimated unreactive fraction (both in c.p.m.)
represents the biological activity of the radiolabelled anti-
body (Trucco & de Petris, 1981).
Determination of n and Ka
The number of antigenic sites, n, on the surface of SW2 cells
capable of interaction with SWAl 1 and the association
constant, K,, were also assessed as described by Trucco & de
Petris (1981). SW2 cells were washed three times in PBS
(with 5% non-fat milk, 0.05% azide) and then dispensed at
5 x 104 cells per tube. A serial two-fold dilution of radio-
labelled SWAIl was performed and 100p1 added to each
tube. The total reaction volume was 0.5ml. The incubation
was carried out at 4°C for 2 h and then the cells were
washed five times as above. The data obtained were manipu-
lated to allow a plot of r against rA-X to be made (where
r is the number of antibody molecules bound per cell and
A -X is the free antibody expressed as c.p.m.). The inter-
actions of SWAl1 with the leukaemic cell line K562 and
human peripheral blood buffy coat were also evaluated using
the same technique in an attempt to estimate the significance
of heterogenous staining of buffy coat and bone marrow
observed by an indirect immunofluorescence test.
The SW2 xenograft model
Female NMRI nu/nu mice were bred within the Biologisches
Zentrallabor, Universitaetsspital, Zurich. Pathogen-free food
and acidified drinking water were given ad libitum. Xeno-
graft passage was performed by subcutaneous transplan-
tation of 2-3mm3 pieces of SW2 tumour into 4-6-week-old
animals. Within approximately three weeks tumours were
ready for use in antibody localisation studies, having reached
a size of approximately 1 cm3.
In vivo localisation studies
The in vivo distribution of SWA 11 was determined by
simultaneous i.v. injection of 20pg (10,uCi) of 131I-labelled
SWAl1 and the same amount and activity of a 125I-labelled
anti-CEA. Both antibodies were of the IgG2a subclass.
Thyroid blocking was achieved by the administration of two
or three drops of Lugol's solution per 100ml of drinking
water. Mice were dissected at days 2, 3, 4 and 7 and the
various organs rinsed in PBS, weighed and counted in a two
channel gamma counter. Localisation of antibody was
expressed in absolute terms as the percentage of injected
dose per gram of tissue (%IDg 1) and in relative terms as a
tissue to blood ratio.
Gamma scintigraphy
Tumour bearing mice were injected intravenously with
100pCi of 131I-labelled SWAI1 (100,uCi per 100,ug) and
then imaged on days 2 and 4 using a pinhole collimator
positioned 9cm from the target animal and linked to a
Picker Dyna Camera 4. Images were generated from 50,000
counts acquired using an energy window of 25% centred on
364keV. No background subtraction technique was required.
Animals were anaesthetised during imaging by intra-
peritoneal injection of 0.5ml Nembutal (1:10 dilution in
PBS). No thyroid blocking was employed in external scinti-
graphy studies.
Results
Antibody characterisation
Our results suggest that the antibody SWAI1 recognises the
small cell carcinoma antigen cluster w4, which was pre-
viously defined by the antibodies SWA21 and SWA22, also
established in our laboratory (Stahel et al., 1988). The
reactivity of these antibodies with cell lines is summarised in
Table I. By indirect immunofluorescence SWA 11 was seen to
react with all nine small cell carcinoma cell lines examined.
With other lung derived lines reactivity was seen in one of
four lines of adenocarcinoma origin, one of three squamous,
none of two large cell and none of two mesothelial. Reacti-
vity was also seen with one of three leukaemic cell lines. A
clear homology was observed between all three antibodies in
terms of pattern of cell line reactivity.
Antibody SWAI1 was unreactive with primary cultures of
normal bronchial epithelial cells but against normal human
peripheral blood buffy coat and bone marrow heterogenous
staining was seen and FACS analysis on the buffy coat has
indicated this to be due to cross-reactivity with 5% of the
total white cell population. This reactivity is confined to
about 40% of mature granulocytes. By agglutination assay
no reactivity of SWAl1 was detected against cells bearing
the red blood cell Ap, A2 B, 0, Rh-hr, Kell, Duffy, Kidd, X
linked, Lewis, MNS or P antigens.
To examine whether the antibodies SWA 1, SWA21 and
SWA22 recognise the same epitope, competition radio-
immunoassays were performed (Table II). Unlabelled
SWA 11 at saturating concentration reduced the binding of
radiolabelled SWA 11 to 10.9% whereas SWA21 and SWA22
reduced binding to 11.1 and 23.0% respectively. Antibody
SWA20, which recognised a different small cell carcinoma
antigen, did not compete with SWAl 1.
In vitro immunoreactivity
The lodogen radiolabelling reagent was employed routinely
to produce iodinated SWAl1 with a specific activity in the
range of 0.5-1.0mCimg-1. The biological activity of the
labelled antibody was generally 65-70%, as shown in
Figure 1 (input 690,000c.p.m. and unreactive fraction
210,000c.p.m.). This figure was subsequently used in calcu-
lations relating to the number of antigenic sites on SW2 cells
and the K. of the interaction.
Determination of n and Ka
Data obtained from the interaction of SWAl1 with the cell
lines SW2 and K562 and with human peripheral blood buffy176 A. SMITH et al.
Table I Antibody reactivity with cell lines and normal tissues by
indirect immunofluorescence and radioimmunoassay
Cell line SWA
Small cell carcinoma (lung) 11 21 22
SW2 + + +
OHI + + +
OH3 + + +
H69 + + +
H128 + + +
H60 + + +
CORL47 + + +
ZL2 + + +
Adenocarcinoma (lung)
SLC52 _ _ _
A549 + + +
A427 - - -
CaLu 6
Squamous (lung)
U1752 _ - _
Hotz + + +
SK-Mes-I -
Large cell (lung)
SLC6 - - -
ZL23 - - -
Mesothelioma (lung)
SPC78 - - -
SPC212 - - -
Leukaemic
K562 + + +
CEM _ _ _
U937 - - -
Normal tissue
Bone marrow +1- +1- +/-
Peripheral blood +/- +/- +/-
Bronchial epithelium
+/-: Small proportion of cells showing heterogenous staining.
Table II Competitive binding assay between SWA20, SWA21,
SWA22 and SWAII
Labelled antibody Unlabelled antibody % Binding8
SWAll None 100
SWAll 10.9
SWA20 107.0
SWA21 11.1
SWA22 23.0
'Expressed as percentage binding of SWAl1 in the absence of
competing antibody.
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Figure 1 Assessment of the biological activity of 1251-labelled
SWA 11. Antibody was incubated with increasing numbers of
SW2 cells as described in the text. The number of counts
remaining unbound was then plotted against the reciprocal of the
cell number. Knowing the input in c.p.m. the biologically active
fraction is determined by extrapolation to the ordinate.
coat were plotted according to the method of Trucco & de
Petris (1981). From the intercepts on the y-axis (=K.) and
the x-axis (=n) the values of Ka are easily obtained. In
Figure 2 the numbers of antigenic sites, n, are equal to
6.1 x 105, 1.1 x 105 and 1.7 x 105 per cell for SW2, K562 and
0
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Figure 2 Determination of the number of SWAl 1 binding sites
on SW2 cells (* *), K562 cells (Cl Cl) and on human
peripheral blood buffy coat (O--- 0) and of the respective
association constants of their interactions. Cells were incubated
with a range of concentrations of 125I-labelled SWAl 1 antibody
and washed, and then the number of bound counts was deter-
mined. The resultant data were manipulated according to Trucco
& de Petris (1981).
human buffy coat respectively and the respective association
constants, K8, are 1.2 x109, 6.8x.108 and 3.6x108M-1.
In vivo localisation
SWAl1 antibody showed strong selective tumour localisation
following i.v. injection into nude mice bearing SCC xeno-
grafts. Tissue to blood ratios of SWAl1 and control anti-
CEA at days 2, 3, 4 and 7 are presented graphically in
Figure 3a and b. Whereas no selective localisation of anti-
CEA was observed, the tumour to blood ratios for SWAl1
were 2.4:1, 5.3:1, 7.5:1 and 8.0:1 at days 2, 3, 4 and 7
respectively. At day 4 the level of tumour accumulated
SWAl1 was 19, 22 and 12 times higher than levels in liver,
kidney and spleen respectively.
The absolute levels of SWAl1 in tumour and various
organs (as %IDg-1) are presented in Table III. SWAI1
displays a high localisation at day 2 with 10.5%IDg-1 of
tumour. The antibody remains bound to the tumour main-
taining 8%IDg-1 on days 3 and 4 and then falling to
4.8%IDg-1 by day 7.
Gamma scintigraphy
The selective accumulation of SWAl1 in SW2 xenografts at
2 and 4 days following injection was confirmed by external
gamma scintigraphy, as displayed in Figure 4a and b
respectively. On day 2 the tumour was already clearly visible
against the background of activity still present in the blood
pool in the visceral organs of the thorax. By day 4 the
background level was markedly reduced, whereas the tumour
remained relatively constant in terms of image intensity. The
unblocked thyroid was visible at this time due to accumu-
lation and relative retention of free 1311.
Discussion
We present in this paper a new monoclonal antibody of
murine origin directed against an SCC-associated antigen.
The strong competition described here between SWAl1 and
SWA21 and 22 and a comparison of their patterns of tissue
reactivity suggest that SWAI1 should also be grouped as
cluster w4 as defined at the International Workshop on
SCC, London, 1987. The antigen defined by SWAl1 is
strongly expressed on the SW2 cell line, with around
6.1 x 105 antigenic binding sites per cell. The association
constant was determined to be 1.2 x 109M-1, a relatively
high value and a good indicator of the high potential of
SWAI1 as a localising agent (Mach et al., 1981).
By comparison with other anti-SCC antibodies described
in the literature the SWAl1 seems to be the most promising
for utilisation in clinical imaging studies and for the delivery
of therapeutically effective amounts of radioisotopes (radio-
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Figure 3 Tissue to blood ratios for antibody SWAl1 (a) and
control anti-CEA antibody (b) at 2, 3, 4 and 7 days after i.v.
injection of 0lCi radiolabelled material. Tu, tumour; Li, liver;
Ki, kidney; Sp, spleen; Lu, lung; He, heart; Th, thyroid; Fe,
femur; Mu, muscle; Br, brain.
Table III Tissue distribution of antibody SWAIP
Day
2 3 4 7
Tumour 10.5 8.0 8.0 4.8
Blood 4.2 1.5 1.1 0.60
Liver 1.9 0.75 0.5 0.22
Kidney 1.4 0.7 0.37 0.12
Spleen 1.8 0.63 0.58 0.35
Lung 1.8 0.82 0.66 0.39
Heart 1.8 0.68 0.33 0.08
Thyroid 2.0 0.84 0.58 0.23
Femur 1.0 0.36 0.25 0.07
Muscle 0.8 0.35 0.18 0.04
Brain 0.25 0.10 0.05 0.013
aExpressed as percentage total injected dose per g
tissue. Each value is a mean obtained from a group of
three animals.
Figure 4 External gamma scintigraphy following i.v. injection of
100pCi 131I-labelled SWAl1. (a) is 2 days post-injection, (b) is 4
days post-injection. The head, h and tumour, t, are indicated. No
background subtraction or thyroid blocking were employed.
immunotherapy or RIT). Stya et al. (1987) have performed
external scintigraphy on SCC xenografts using the antibodies
UM-MS 1, 2 and 3 despite tumour to blood ratios often
lower than one and a highest tumour to tissue ratio of
18.5:1 against muscle. The absolute amount of antibody
localising to tumour had a mean value of 1.2%IDg-I at day
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10 (Stya et al., 1987). Studies on the IgM anti-SCC antibody
MAb(600D 1) indicated tumour localisation of 3%IDg-1 at
day 7 after injection but with poor tumour to normal tissue
ratios (Zimmer et al., 1985). The MAb 8 anti-SCC antibody
has been shown to display unusual kinetics in that tumour
accumulation progressed gradually throughout the study up
to day 7, when a level of 7.4%IDg-1 was reached. However,
the tumour to blood ratio at this point was only 2.7:1 and
ratios for tumour to lung, kidney and liver were 5, 11 and
9:1 respectively (Endo et al., 1987). Our studies on SWAl1
have shown localisation to tumour of 10.4%IDg-1 at day 2,
around 8% at days 3 and 4 and 4.8% at day 7. Tumour to
blood levels at the corresponding times were markedly better
than those reported for other antibodies at 2.4, 5.3, 7.5 and
8:1. A representative sample of tumour to organ antibody
levels at day 4 shows similarly high ratios at 19, 22, 12 and
44:1 for liver, kidney, spleen and muscle respectively.
The treatment of small cell cancer of the lung by RIT may
prove particularly appropriate in view of the high radiosensi-
tivity of the classic phenotype of the disease. SCC is highly
invasive, often presenting in a widely disseminated form (De
Leij et al., 1987; Stahel et al., 1985a), and despite the very
high initial sensitivity of the disease to chemotherapy it is
prone to the rapid emergence of resistance to this form of
attack. Such disseminated tumours have already been sug-
gested as promising cases for the application of RIT (Dykes
et al., 1987). The emergent refractory form of the disease
presumably originates from residual viable cells following
first treatment and such residual cells may be more suscept-
ible to the use of conventional chemotherapeutic protocols in
conjunction with RIT as a combined modality. RIT has
shown variable success in the treatment of human tumour
xenografts grown in rodent models. In one study complete
ablation of a radiosensitive neuroblastoma has been reported
(Cheung et al., 1986) but other reports show a high depen-
dency on the age of the tumour, with only limited inhibition
of growth in those which are well established (Epenetos,
1984; Badger et al., 1986; Sharkey et al., 1987). In view of
the high localising capacity of SWAl1, its persistence at the
tumour, its accompanying low blood and normal tissue
levels and the inherent radiosensitivity of SCC we are now
encouraged to examine the efficacy of SWAl1 as a radio-
immunotherapeutic agent in our xenograft model system.
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